New Delhi: Alliance for Medicinal Research, Innovation, Translation & Value Acceleration – AMRITVA Cohort 2 was unveiled alongside the signing of a Memorandum of Understanding (MoU) between the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli and Boehringer Ingelheim India Pvt. Ltd. to advance pharmaceutical education and research in the country.
The MoU was signed in the presence of Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, in New Delhi.
The launch of AMRITVA Cohort 2 marks a continued push to strengthen India’s innovation ecosystem and accelerate the translation of research outcomes into viable pharmaceutical products and entrepreneurial ventures.
AMRITVA is implemented by the Startup Incubation and Innovation Centre (SIIC), in partnership with NIPER Raebareli. The initiative is supported under Corporate Social Responsibility (CSR) by Boehringer Ingelheim India Pvt. Ltd.
Also Read: Biopharma SHAKTI Announced in Union Budget 2026-27 with ₹10,000 Crore Outlay
Addressing the gathering, Shri Manoj Joshi underscored the importance of collaborative partnerships between academia and industry in strengthening the research-to-market pipeline.
He noted that such initiatives are critical for advancing domestic innovation capabilities, encouraging entrepreneurship, and ensuring wider access to cost-effective healthcare solutions.
The unveiling of AMRITVA Cohort 2, he indicated, aligns with broader efforts to build a robust pharmaceutical innovation ecosystem in India.
The event was also attended by Awadhesh Kumar Choudhary, Senior Economic Advisor, Department of Pharmaceuticals; Anugraha P, Director, Department of Pharmaceuticals; and Ashutosh Agnihotri, Chief Executive Officer of SIIC, IIT Kanpur.
AMRITVA Cohort 2: Five Innovators Selected to Receive Grant Support
- Under AMRITVA Cohort 2, five innovators have been selected to receive grant support aimed at facilitating the commercialization of their research.
- Financial assistance of ₹8 lakh each has been awarded to three faculty-led projects, while two research scholar-led projects have received ₹6 lakh each.
- The grant support under AMRITVA Cohort 2 is intended to accelerate translational research and enable market-ready pharmaceutical innovations.
Also Read: Scaling Pharma Exports: India Targets Double-Digit Growth After Crossing USD 30 Billion
The MoU between Boehringer Ingelheim India and NIPER Raebareli, including its Centre of Excellence for Novel Drug Delivery Systems (CoE-NDDS), establishes a structured framework to strengthen academic and research collaboration.
The partnership will focus on pharmaceutical technologies, novel drug delivery systems, academic exchange, and capability-building programmes.
Through this collaboration, AMRITVA Cohort 2 is expected to benefit from enhanced industry-academia integration and research support mechanisms.
As part of the agreement, Boehringer Ingelheim India will provide researchers and institutions access to its opnMe® open science platform, enabling scientific exchange and accelerating innovation in healthcare.
The initiative complements the objectives of AMRITVA Cohort 2 by facilitating access to global scientific resources and fostering collaborative research.
The Department of Pharmaceuticals continues to support the sector’s transition from a volume-driven to a value-driven model through focused policy interventions, infrastructure development, strengthened industry-academia partnerships, and incubation-led commercialization efforts.
The launch of AMRITVA Cohort 2 is aligned with these strategic priorities and with the broader national vision of Viksit Bharat 2047.
